Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
-
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
-
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
-
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
-
Alkermes plc Reports Second Quarter 2026 Financial Results
-
Alkermes to Report Second Quarter Financial Results on July 28, 2026
-
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
-
Alkermes Files Patent Litigation Against Teva, Apotex, MSN Pharmaceuticals
Trading Information
- Previous Close Price
- $40.54
- Day Range
- $40.32–41.96
- 52-Week Range
- $27.00–55.67
- Bid/Ask
- $41.68 / $41.85
- Shares Outstanding
- 167.76M
- Market Cap
- $7.00B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 23.82
- Price/Sales
- 4.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.41%
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,050
- Website
- https://www.alkermes.com
Competitors
Valuation
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Price/Earnings (Normalized) | 23.82 | 23.82 |
Price/Book Value | 3.76 | 7.33 |
Price/Sales | 4.08 | 6.44 |
Price/Cash Flow | 19.22 | 22.07 |
Price/Earnings
ALKS
JNJ
Financial Strength
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Quick Ratio | 1.68 | 0.73 |
Current Ratio | 2.30 | 1.09 |
Interest Coverage | 2.00 | 25.00 |
Quick Ratio
ALKS
JNJ
Profitability
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Return on Assets (Normalized) | 5.23% | 13.42% |
Return on Equity (Normalized) | 9.41% | 32.69% |
Return on Invested Capital (Normalized) | 7.39% | 20.33% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|sRbsK%n | LOCK|FSwy | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|JK&kN&> | LOCK|<$?g | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|<Hg>$@ | LOCK|mh | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|<hRXJt^ | LOCK|cqs | $29B | |||
| Viatris Inc
VTRS
| LOCK|^t$$hF | LOCK|BF | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|kz& | LOCK|xPn | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|Kr>Yq$Y | LOCK|&RP | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|qx#rVW | LOCK|^F | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|v%fTTg | LOCK|Wlxn> | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|#jx?zW< | LOCK|VF& | $2B |
United States